NMDA-receptor antagonist; deriv of adamantane, q.v. Prepn of the hydrochloride: K. Gerzon et al., J. Med. Chem. 6, 760 (1963); of the free base and hydrochloride: J. Mills, E. Krumkalns, US 3391142 (1968 to Lilly). Series of articles on pharmacology and metabolism: Arzneim.-Forsch. 27, 1471-1489 (1977); on neuropharmacology and clinical efficacy: ibid. 32, 1236-1276 (1982). Pharmacodynamics and pharmacokinetics: W. Wesemann et al., ibid. 33, 1122 (1983). NMDA-receptor binding study: J. Kornhuber et al., Eur. J. Pharmacol. 166, 589 (1989); and neuroprotective properties: idem et al., J. Neural Transm. 43, Suppl., 91 (1994). Clinical studies as antispasmodic: H. Rohde, Fortschr. Med. 100, 2023 (1982); in senile dementia: R. Grtelmeyer, H. Erbler, Arzneim.-Forsch. 42, 904 (1992). Review of clinical experience in neurodegenerative disorders: K. K. Jain, Expert Opin. Invest. Drugs 9, 1397-1406 (2000).
Neuroprotective; antispasmodic; antiparkinsonian.
Antiparkinsonian; Antispasmodic; NMDA Receptor Antagonist; Neuroprotective